Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate |
Security Level |
|
Mechanism |
Felbamate: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Felbamate. |
Management |
Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent. |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of Felbamate
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate
Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate |
Security Level |
|
Mechanism |
Felbamate: PHENobarbital may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of PHENobarbital. |
Management |
In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce phenobarbital dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects. |
No comments yet.
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs Felbamate Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of Felbamate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.